Exact Sciences (NASDAQ:EXAS) Stock Unloaded Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Exact Sciences Corporation (NASDAQ:EXAS). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in Exact Sciences stock on March 24th. The trade occurred in the Representative’s “GABRIELLE ASHTYN HERN TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Exact Sciences Price Performance

EXAS stock opened at $104.91 on Tuesday. The stock’s 50 day simple moving average is $103.62 and its 200 day simple moving average is $90.07. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $104.98. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.17 and a current ratio of 2.43. The company has a market cap of $20.03 billion, a P/E ratio of -95.37, a price-to-earnings-growth ratio of 2.02 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Friday, February 13th. The medical research company reported ($0.21) EPS for the quarter, missing the consensus estimate of $0.08 by ($0.29). The company had revenue of $878.38 million during the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The business’s revenue for the quarter was up 23.1% compared to the same quarter last year. During the same period last year, the company earned ($0.06) earnings per share. On average, research analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on EXAS shares. BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research report on Thursday, January 22nd. Zacks Research downgraded Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Evercore set a $105.00 price target on Exact Sciences and gave the company an “in-line” rating in a research report on Monday, January 5th. Finally, Mizuho reaffirmed a “neutral” rating and set a $105.00 price target (up from $85.00) on shares of Exact Sciences in a research report on Tuesday, January 20th. Twenty-one investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Exact Sciences has a consensus rating of “Reduce” and a consensus price target of $92.13.

Hedge Funds Weigh In On Exact Sciences

Large investors have recently made changes to their positions in the stock. Marshall Wace LLP boosted its stake in Exact Sciences by 1,553.1% during the second quarter. Marshall Wace LLP now owns 429,719 shares of the medical research company’s stock valued at $22,835,000 after buying an additional 403,724 shares during the period. Holocene Advisors LP boosted its stake in Exact Sciences by 189.5% during the second quarter. Holocene Advisors LP now owns 2,145,181 shares of the medical research company’s stock valued at $113,995,000 after buying an additional 1,404,086 shares during the period. Fisher Asset Management LLC boosted its stake in Exact Sciences by 25.5% during the third quarter. Fisher Asset Management LLC now owns 198,287 shares of the medical research company’s stock valued at $10,848,000 after buying an additional 40,258 shares during the period. Assenagon Asset Management S.A. bought a new stake in Exact Sciences during the fourth quarter valued at $47,848,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Exact Sciences by 643.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,286,595 shares of the medical research company’s stock valued at $70,390,000 after buying an additional 1,113,459 shares during the period. 88.82% of the stock is owned by institutional investors.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.